1. Lilly says its monoclonal antibody prevented COVID-19 infections in trial — Roche gets priority review on blockbuster IPF drug — California says batch of Moderna vaccine is safe, despite reports of illnesses — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice

Good people selling crappy product

Discussion in 'Aerie Pharma' started by anonymous, Apr 18, 2018 at 7:34 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Oh well, it’s a foot in the door. Side effect profile will kill the product at launch.
     

  2. anonymous

    anonymous Guest

    It's a ROC inhibitor! What the hell do people expect! Of course its going to fail. Can only imagine the extreme formulation to get this in solution in the first place!
     
  3. anonymous

    anonymous Guest

    Rhopressa lights up the eye like a vicious sunburn in July! One of my docs mentioned that Rhopressa's efficacy is Rescula part 2. When I looked up Rescula - I saw it was removed from the market.
     
  4. anonymous

    anonymous Guest

    Do you feel better now?
     
  5. anonymous

    anonymous Guest

    soon....
     
  6. anonymous

    anonymous Guest

    The big question since Aerie was so thrilled about the thousands of resumes they got for sales positions is has anyone actually sold any of this product yet?
     
  7. anonymous

    anonymous Guest

    0 scripts so far but lots of glad handing happening!
     
  8. anonymous

    anonymous Guest

    People who dont work here dont have a clue. The bigger question is what is provoking the insecure, paranoid schizo rants from outsiders? Pretty bizarre behavior for such old pros
     
  9. anonymous

    anonymous Guest

    The glaucoma market will shift back to Allergan Lumigan after the successful phase 3 data on the time released injectable. Eliminates a generic force on the market and apparently the patient demographics responded well to this delivery option. Better patient compliance and only twice per year. Aerie will be in business for a short while.
     
  10. anonymous

    anonymous Guest

    The same folks that failed at their last 3-4 companies will also fail at this one.

    Pin It
     
  11. anonymous

    anonymous Guest

    So should I sell my stock now? What about the follow up combination therapy with latanoprost?
     
  12. anonymous

    anonymous Guest

    The salty person must be someone that didn’t get hired.
     
  13. anonymous

    anonymous Guest

    What patient demographics responded well? The people in the bimatoprost SR study? I would hope so seeing as how they were being studied. Ever hear of the term Practice Inertia? One phase 3 study on implants is not going to suddenly stop docs from using drops. Your theories on Aerie have gone from stupid to stupidest to stupidester. We need a new word for you now.
     
  14. anonymous

    anonymous Guest




    Look at this wanks reply! LOL! Always the last one to say told you so. Drops????? Drops will be a thing of the past my friend. Get up to speed with what new delivery vehicles will replace drops. Can a Rock inhibitor be put in solution in order to get a drop out of it? Is moon dust soluble? What causes the hyperemia and inflammation? Is that the insoluble drug or actual plastic etched off the ampule?
     
  15. anonymous

    anonymous Guest

    I've worked for a lot of drug companies and there is not a single thread on a single company board that has anything positive to say. FAKE NEWS!

    Seeing as this is a small company with a relatively small sales force, I'll put my 2 cents in. The folks that don't work for the company who are trashing it don't know what they're talking about.

    Is Rhopressa crap? Nope. Will Roclatan be better? As long as the company can make nice nice with the insurance companies.

    Anyone on here trashing Aerie and the drug don't work here. If they're in the field and trashing this drug, they're nuts.

    Go show us where the grass is greener in pharma sales these days?
    Go sell an immuno therapy in onology.
    Go sell a rare disease drug for a company like mallinkrodt.
    I've haven't been in oph but I get the feeling the folks trash talking tiny wittle Aerie are malcontents from some other eye popping company like Allergy Gan or Bomb and Lam or Shitter. Shire of course, being a piece of sh*t company slammed with some serious fines in their other divisions like rare disease.
    Selling eye drops is monkey biz.
    Sell a physician administered drug in a complex market like oncology or auto-immune disease or rare disease and see what that's like.
    Bottom Line: screw the trash talking trolls and enjoy the Aerie ride as long as you can.
    If you're a high stakes gambler, buy the stock and hope the company gets bought.
    But you won't be able to retire.
    However, if you bought 2,500 shares of Gilead stock in 1992 and sold it 2 years ago, you'd be retired.
     
  16. anonymous

    anonymous Guest

    I should never have left Shire!! This company sucks big time - - - crappy product and micro managers!! SOS!
     
  17. anonymous

    anonymous Guest

    LOL!!!! You must be sucking if being micromanaged....
     
  18. anonymous

    anonymous Guest

    I’ve got one of the highest Rx volumes in my district and I’m being micro managed. Management better get a clue and quick. I know someone who is already thinking about calling HR because of the way their manager is treating them. There’s a difference between normal sales expectations/pressure and disrespect.
     
  19. anonymous

    anonymous Guest

    I HATE this job! Already looking.
     
  20. anonymous

    anonymous Guest

    This company SUCKS!!